



## Immutep Limited Class Action Lawsuit - IMMP

Immutep Limited  
NASDAQ: IMMP

---

### Affected IMMP Investor Summary

- **Who:** Immutep Limited ([NASDAQ: IMMP](#))
  - **What:** Securities fraud class action lawsuit filed
  - **Class Period:** March 24, 2025 through March 12, 2026
  - **Deadline to Seek Lead Plaintiff Status:** July 6, 2026
  - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's lead product candidates prospects
  - **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](http://www.ktmc.com) for recovery options
- 

The *Immutep Limited* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Immutep Limited* ("*Immutep*") (NASDAQ: IMMP) American Depositary Receipts ("ADRs") between March 24, 2025 and March 12, 2026, inclusive (the "Class Period"). Captioned *Yves Dhaenens v. Immutep Limited*, No. 26-cv-03705 (S.D.N.Y.), the *Immutep* class action lawsuit alleges that *Immutep* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

**If you lost money as a result of your *Immutep* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at [info@ktmc.com](mailto:info@ktmc.com). Lead plaintiff motions must be filed with the court no later than July 6, 2026.**

### COMPLAINT ALLEGATION SUMMARY:

*Immutep* is a biotechnology company that was conducting its TACTI-004 Phase III trial evaluating eftilagimod alfa ("efti") as a treatment for patients with advanced lung cancer.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the company misrepresented the TACTI-004 trial status and prospects based on efti's performance in prior studies; (2) the existing information for the TACTI-004 trial indicated that there was a risk it would fail to meet its primary efficacy and/or safety endpoints; and (3) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

### **WHY DID IMMUTEP'S STOCK DROP?**

On March 13, 2026, *Immutep* announced that the Independent Data Monitoring for the TACTI-004 study recommended that the trial be discontinued following a planned interim futility analysis. On this news, the price of *Immutep's* stock fell about 83%.

### **THE LEAD PLAINTIFF PROCESS:**

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Immutep* ADRs during the Class Period to seek appointment as lead plaintiff in the *Immutep* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

### **ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:**

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

